Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03616821
Registration number
NCT03616821
Ethics application status
Date submitted
1/08/2018
Date registered
6/08/2018
Date last updated
9/11/2023
Titles & IDs
Public title
Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis
Query!
Scientific title
A 54-Week, Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel-group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis (Expedition Lead-in)
Query!
Secondary ID [1]
0
0
Legacy #3151-201-008
Query!
Secondary ID [2]
0
0
D5272C00001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Expedition
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Ulcerative Colitis
0
0
Query!
IBD
0
0
Query!
Condition category
Condition code
Oral and Gastrointestinal
0
0
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Oral and Gastrointestinal
0
0
0
0
Query!
Inflammatory bowel disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Brazikumab
Treatment: Drugs - Placebo
Experimental: Brazikumab Dose 1 - Intravenous brazikumab on day 1, day 15, and day 43 followed by Subcutaneous brazikumab every 4 weeks beginning on day 71 through week 50
Experimental: Brazikumab Dose 2 - Intravenous brazikumab on day 1, day 15, and day 43 followed by Subcutaneous brazikumab every 4 weeks beginning on day 71 through Week 50
Placebo Comparator: Placebo - Intravenous placebo on day 1, day 15, and day 43 followed by Subcutaneous every 4 weeks beginning on day 71 through Week 50.
Treatment: Drugs: Brazikumab
Intravenous brazikumab on day 1, day 15, and day 43 followed by Subcutaneous brazikumab every 4 weeks beginning on day 71 through Week 50
Treatment: Drugs: Placebo
Intravenous placebo on day 1, day 15, and day 43 followed by Subcutaneous placebo every 4 weeks beginning on Day 71 through Week 50.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of participants with clinical remission
Query!
Assessment method [1]
0
0
Clinical remission defined as: Modified Mayo Score (mMS): Endoscopy subscore = 0 or 1, AND Rectal bleeding subscore = 0, AND Stool frequency subscore = 0 or 1 AND at least a 1 point decrease from baseline
Query!
Timepoint [1]
0
0
at Week 10
Query!
Secondary outcome [1]
0
0
Percentage of participants with sustained clinical remission
Query!
Assessment method [1]
0
0
Sustained clinical remission defined as Modified Mayo Score (mMS): Endoscopy subscore = 0 or 1, AND Rectal bleeding subscore = 0, AND Stool frequency subscore = 0 or 1 AND at least a 1 point decrease from baseline
Query!
Timepoint [1]
0
0
at both Week 10 and Week 54
Query!
Secondary outcome [2]
0
0
Percentage of participants with CS-free clinical remission
Query!
Assessment method [2]
0
0
CS-free clinical remission defined as mMS: Endoscopy subscore = 0 or 1, AND Rectal bleeding subscore = 0, AND Stool frequency subscore = 0 or 1 AND at least a 1 point decrease from baseline
Query!
Timepoint [2]
0
0
at Week 54 for patients who are CS-free for at least the last 12 weeks before the assessment at Week 54
Query!
Secondary outcome [3]
0
0
Percentage of participants with clinical response
Query!
Assessment method [3]
0
0
Clinical response is defined as Reduction in mMS = 2 points from baseline AND = 30% from baseline AND a decrease in the rectal bleeding score = 1 point from baseline or a score of 0 or 1
Query!
Timepoint [3]
0
0
at Week 10
Query!
Secondary outcome [4]
0
0
Percentage of participants with endoscopic improvement
Query!
Assessment method [4]
0
0
Endoscopic improvement is defined as Endoscopy subscore = 1
Query!
Timepoint [4]
0
0
at Week 10
Query!
Secondary outcome [5]
0
0
Serum concentration of brazikumab
Query!
Assessment method [5]
0
0
Pharmacokinetics: concentration of brazikumab in serum
Query!
Timepoint [5]
0
0
through Week 68
Query!
Secondary outcome [6]
0
0
For each dose level: LS mean of Mayo score and brazikumab pre-dose blood concentration
Query!
Assessment method [6]
0
0
Exposure-response
Query!
Timepoint [6]
0
0
at 12 weeks after dosing
Query!
Secondary outcome [7]
0
0
Incidence of anti-drug antibodies
Query!
Assessment method [7]
0
0
Immunogenicity: incidence of brazikumab anti-drug antibodies in serum
Query!
Timepoint [7]
0
0
through week 68
Query!
Secondary outcome [8]
0
0
Number and percentage of participants with adverse events
Query!
Assessment method [8]
0
0
Number and percentage of patients with reported adverse events.
Query!
Timepoint [8]
0
0
through Week 68
Query!
Secondary outcome [9]
0
0
Percentage of participants with potentially clinically significant changes in laboratory values
Query!
Assessment method [9]
0
0
Percentage of patients with potentially clinically significant changes in hematology, clinical chemistry, urinalysis.
Query!
Timepoint [9]
0
0
through Week 68
Query!
Secondary outcome [10]
0
0
Percentage of participants with potentially clinically significant changes in vital signs
Query!
Assessment method [10]
0
0
Percentage of patients with potentially clinically significant changes in systolic and diastolic blood pressure, and pulse rate.
Query!
Timepoint [10]
0
0
through Week 68
Query!
Secondary outcome [11]
0
0
Clinically relevant abnormal findings at physical exam
Query!
Assessment method [11]
0
0
New or aggregated clinical relevant abnormal medical finding are reported as AE unless related to the disease under study
Query!
Timepoint [11]
0
0
through Week 68
Query!
Secondary outcome [12]
0
0
Percentage of participants with potentially clinically significant changes in ECGs
Query!
Assessment method [12]
0
0
Percentage of patients with potentially clinically significant changes in 12-lead ECG recordings
Query!
Timepoint [12]
0
0
through Week 68
Query!
Eligibility
Key inclusion criteria
1. Ability to provide informed consent
2. Aged 18 to 80 years of age
3. Diagnosis of UC with an onset of symptoms for a minimum of 3 months prior to Screening
4. Evidence of UC extending proximal to the rectum (= 15 cm of involved colon)
5. Moderately to severely active UC as defined by:
1. Average daily mMS Stool Frequency subscore = 1 AND Average daily mMS Rectal
Bleeding subscore = 1
2. Modified Mayo endoscopic subscore of = 2 based on a full colonoscopy within 14
days prior to randomization.
6. Participant had an inadequate response or intolerance to intervention with
conventional treatment or prior biological treatment or demonstrated CS dependence for
the treatment of UC. For participants who have previously used biological treatment, a
participant may have failed up to 3 biologics that include up to 2 different
mechanisms of action.
7. Participants taking 5-aminosalicylates, oral prednisone (or equivalent), oral
budesonide, or immunomodulators must be at a stable dose or discontinued. Topical
(rectal) aminosalicylic acid or topical (rectal) steroids should be discontinued.
8. Female participants of childbearing potential must have a negative urine pregnancy
test prior to administration of study intervention and must agree to use a highly
effective method of birth control throughout the study and for at least 18 weeks after
the last dose of study intervention.
9. Women not of childbearing potential are defined as women who are either permanently
sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who
are postmenopausal.
10. Non sterilized males who are sexually active with a female partner of childbearing
potential should use condoms during treatment and until the end of relevant systemic
exposure in the male participant, plus a further 18 weeks.
11. No known history of active TB or latent TB without completion of appropriate
intervention and negative QFT-TB during Screening.
Complete inclusion criteria are in the Clinical Study Protocol
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
80
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Participant has UC limited to the rectum (ie, not beyond 15 cm of the anal verge).
2. Current diagnosis of fulminant colitis, a diagnosis of CD or indeterminate colitis,
presence or history of a fistula consistent with CD, primary sclerosing cholangitis,
celiac disease, or untreated bile acid malabsorption. Participants with a history of
toxic megacolon within 12 months of screening are excluded.
3. History of subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch,
Koch pouch, ileostomy, or other prior colonic resection, or need for surgical
intervention for control of UC anticipated within 6 months.
4. Participant has received the following treatment:
1. Infliximab: within 8 weeks prior to randomization.
2. Adalimumab, certolizumab pegol, or golimumab: within 8 weeks prior to
randomization.
3. Vedolizumab or ustekinumab within 12 weeks of randomization.
4. Other prohibited medication, biologic or small molecule treatment within 5
half-lives prior to randomization.
5. Fecal microbiota transplantation: within 8 weeks prior to randomization.
5. Criterion deleted as part of Amendment 5 v6.0
6. Except for ustekinumab, prior exposure to any biologic agent targeting IL-12 or IL-23.
7. Known history of allergy to the study intervention formulation or any of its
excipients or components of the delivery device, or to any other biologic therapy.
8. Participant received cyclosporine, mycophenolate mofetil, sirolimus (rapamycin),
thalidomide, tacrolimus (FK-506), or tofacitinib within 2 weeks prior to Screening.
9. Participants who received IV or intramuscular steroids within 2 weeks prior to
Screening.
10. Participant is currently enrolled in another investigational device or drug study, or
is within 35 days or 5 half-lives, whichever is longer, since ending another
investigational device or drug study(s), or receiving other investigational agent(s).
11. Participant received a transfusion of blood, plasma, or platelets within 30 days prior
to Screening.
12. Participant received a Bacille Calmette-Guérin vaccination within 12 months of
randomization or any other live vaccine less than 4 weeks prior to randomization.
13. Participant has any of the following criteria related to infections:
1. Evidence of a recent systemic fungal infection, requiring inpatient
hospitalization, and/or antifungal treatment.
2. Any infection requiring hospitalization or treatment with IV anti-infectives
within 4 weeks of Screening.
3. Cytomegalovirus or Epstein-Barr virus infection that has not resolved within 8
weeks prior to Screening.
4. Clinically significant chronic infection that has not resolved within 8 weeks of
Screening.
5. Nonserious infection requiring oral anti-infectives within 2 weeks prior to
randomization must be further discussed with study medical monitor.
6. Clinical evidence of or suspected to have an abscess during Screening.
7. Any underlying condition that predisposes the participant to infections.
8. Participant had previous allogenic bone marrow transplant or history of organ or
cell-based transplantation.
9. Clinically significant active infection or signs/symptoms of infection that has
the potential to worsen with immunosuppressive therapy.
10. Signs or symptoms of ongoing infection due to intestinal pathogens.
14. Participant has known or suspected history of chronic use of NSAIDs and/or opiates,
drug, or alcohol abuse.
15. History of cancer with the following exceptions: history of basal cell carcinoma
and/or squamous cell carcinoma of the skin OR carcinoma in situ of the cervix; with
apparent successful curative therapy, greater than 12 months prior to Screening.
16. Clinically significant cardiovascular conditions.
17. Prolonged QTcF interval or conditions leading to additional risk for QT prolongation.
18. Clinically significant kidney disease
19. Abnormal laboratory results at Screening as defined in the study protocol
20. Participant is pregnant or breastfeeding or plans to become pregnant during the study.
21. Participant has other known, pre-existing, clinically significant medical conditions
that are not associated with UC and are uncontrolled with standard treatment.
22. Participant has any disorder that may compromise the ability of the participant to
give written informed consent and/or to comply with all required study procedures.
23. Employees of the clinical study site or any other individuals involved with the
conduct of the study, or immediate family members of such individuals.
Complete exclusion criteria are in the Clinical Study Protocol
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
7/08/2018
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
23/10/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
242
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arkansas
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Georgia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Illinois
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Indiana
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Kansas
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Louisiana
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Michigan
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Mississippi
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Nevada
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
New York
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
North Carolina
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Ohio
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Oklahoma
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Pennsylvania
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Texas
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Virginia
Query!
Country [21]
0
0
Canada
Query!
State/province [21]
0
0
Quebec
Query!
Country [22]
0
0
Czechia
Query!
State/province [22]
0
0
Brno
Query!
Country [23]
0
0
Czechia
Query!
State/province [23]
0
0
Ceske Budejovice
Query!
Country [24]
0
0
Czechia
Query!
State/province [24]
0
0
Hradec Kralove
Query!
Country [25]
0
0
Czechia
Query!
State/province [25]
0
0
Ostrava
Query!
Country [26]
0
0
Germany
Query!
State/province [26]
0
0
Hamburg
Query!
Country [27]
0
0
Germany
Query!
State/province [27]
0
0
Kiel
Query!
Country [28]
0
0
Germany
Query!
State/province [28]
0
0
Ulm
Query!
Country [29]
0
0
Hungary
Query!
State/province [29]
0
0
Debrecen
Query!
Country [30]
0
0
India
Query!
State/province [30]
0
0
Bangalore
Query!
Country [31]
0
0
India
Query!
State/province [31]
0
0
Hyderabad
Query!
Country [32]
0
0
India
Query!
State/province [32]
0
0
Jaipur
Query!
Country [33]
0
0
India
Query!
State/province [33]
0
0
New Delhi
Query!
Country [34]
0
0
India
Query!
State/province [34]
0
0
Rajkot
Query!
Country [35]
0
0
India
Query!
State/province [35]
0
0
Surat
Query!
Country [36]
0
0
Israel
Query!
State/province [36]
0
0
Haifa
Query!
Country [37]
0
0
Israel
Query!
State/province [37]
0
0
Jerusalem
Query!
Country [38]
0
0
Israel
Query!
State/province [38]
0
0
Petah Tikva
Query!
Country [39]
0
0
Italy
Query!
State/province [39]
0
0
Milano
Query!
Country [40]
0
0
Italy
Query!
State/province [40]
0
0
Negrar
Query!
Country [41]
0
0
Italy
Query!
State/province [41]
0
0
Rho
Query!
Country [42]
0
0
Italy
Query!
State/province [42]
0
0
Roma
Query!
Country [43]
0
0
Japan
Query!
State/province [43]
0
0
Asahikawa-shi
Query!
Country [44]
0
0
Japan
Query!
State/province [44]
0
0
Chiba-shi
Query!
Country [45]
0
0
Japan
Query!
State/province [45]
0
0
Fukuoka-shi
Query!
Country [46]
0
0
Japan
Query!
State/province [46]
0
0
Fukuyama-shi
Query!
Country [47]
0
0
Japan
Query!
State/province [47]
0
0
Hakodate-shi
Query!
Country [48]
0
0
Japan
Query!
State/province [48]
0
0
Kasama-shi
Query!
Country [49]
0
0
Japan
Query!
State/province [49]
0
0
Kashiwa-shi
Query!
Country [50]
0
0
Japan
Query!
State/province [50]
0
0
Koshigaya-shi
Query!
Country [51]
0
0
Japan
Query!
State/province [51]
0
0
Kure-shi
Query!
Country [52]
0
0
Japan
Query!
State/province [52]
0
0
Minato-ku
Query!
Country [53]
0
0
Japan
Query!
State/province [53]
0
0
Nagaoka-shi
Query!
Country [54]
0
0
Japan
Query!
State/province [54]
0
0
Onga-gun
Query!
Country [55]
0
0
Japan
Query!
State/province [55]
0
0
Sapporo-shi
Query!
Country [56]
0
0
Japan
Query!
State/province [56]
0
0
Takarazuka-shi
Query!
Country [57]
0
0
Korea, Republic of
Query!
State/province [57]
0
0
Busan
Query!
Country [58]
0
0
Korea, Republic of
Query!
State/province [58]
0
0
Daegu
Query!
Country [59]
0
0
Korea, Republic of
Query!
State/province [59]
0
0
Seoul
Query!
Country [60]
0
0
Korea, Republic of
Query!
State/province [60]
0
0
Wonju-si
Query!
Country [61]
0
0
Poland
Query!
State/province [61]
0
0
Bydgoszcz
Query!
Country [62]
0
0
Poland
Query!
State/province [62]
0
0
Chojnice
Query!
Country [63]
0
0
Poland
Query!
State/province [63]
0
0
Czestochowa
Query!
Country [64]
0
0
Poland
Query!
State/province [64]
0
0
Gdansk
Query!
Country [65]
0
0
Poland
Query!
State/province [65]
0
0
Kraków
Query!
Country [66]
0
0
Poland
Query!
State/province [66]
0
0
Ksawerów
Query!
Country [67]
0
0
Poland
Query!
State/province [67]
0
0
Piaseczno
Query!
Country [68]
0
0
Poland
Query!
State/province [68]
0
0
Poznan
Query!
Country [69]
0
0
Poland
Query!
State/province [69]
0
0
Rzeszow
Query!
Country [70]
0
0
Poland
Query!
State/province [70]
0
0
Sopot
Query!
Country [71]
0
0
Poland
Query!
State/province [71]
0
0
Torun
Query!
Country [72]
0
0
Poland
Query!
State/province [72]
0
0
Warszawa
Query!
Country [73]
0
0
Poland
Query!
State/province [73]
0
0
Wroclaw
Query!
Country [74]
0
0
Puerto Rico
Query!
State/province [74]
0
0
San Juan
Query!
Country [75]
0
0
Russian Federation
Query!
State/province [75]
0
0
Aramil
Query!
Country [76]
0
0
Russian Federation
Query!
State/province [76]
0
0
Izhevsk
Query!
Country [77]
0
0
Russian Federation
Query!
State/province [77]
0
0
Moscow
Query!
Country [78]
0
0
Russian Federation
Query!
State/province [78]
0
0
Novosibirsk
Query!
Country [79]
0
0
Russian Federation
Query!
State/province [79]
0
0
Perm
Query!
Country [80]
0
0
Russian Federation
Query!
State/province [80]
0
0
Tomsk
Query!
Country [81]
0
0
Slovakia
Query!
State/province [81]
0
0
Kosice
Query!
Country [82]
0
0
South Africa
Query!
State/province [82]
0
0
Bloemfontein
Query!
Country [83]
0
0
South Africa
Query!
State/province [83]
0
0
Cape Town
Query!
Country [84]
0
0
South Africa
Query!
State/province [84]
0
0
Plumstead
Query!
Country [85]
0
0
Spain
Query!
State/province [85]
0
0
Valencia
Query!
Country [86]
0
0
Taiwan
Query!
State/province [86]
0
0
Taichung
Query!
Country [87]
0
0
Taiwan
Query!
State/province [87]
0
0
Taipei
Query!
Country [88]
0
0
Ukraine
Query!
State/province [88]
0
0
Kyiv
Query!
Country [89]
0
0
Ukraine
Query!
State/province [89]
0
0
Vinnytsia
Query!
Country [90]
0
0
United Kingdom
Query!
State/province [90]
0
0
West Bromwich
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
AstraZeneca
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The present study (D5272C00001/Legacy #3151-201-008) aims to evaluate the efficacy and safety
of brazikumab in patients with moderately to severely active UC and will include assessments
of clinical responses as demonstrated by improvement of symptoms and of colonic mucosal
appearance as observed on endoscopy
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03616821
Query!
Trial related presentations / publications
Query!
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed
Query!
Contacts
Principal investigator
Name
0
0
Kathy Bohannon
Query!
Address
0
0
AstraZeneca
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT03616821
Download to PDF